Immuto Scientific and University of Wisconsin–Madison Announce Collaboration to Advance Discovery of Novel Cancer Targets
Immuto Scientific announced today a collaborative agreement with the University of Wisconsin–Madison to identify disease-specific, novel therapeutic targets in colorectal cancer using Immuto’s proprietary structural surfaceomics platform. The collaboration, led at UW by Dustin Deming, M.D., professor of medicine and leading expert in colorectal cancer, provides Immuto Scientific with access to uniquely characterized patient-derived organoid models representing microsatellite stable colorectal cancer.
Immuto Scientific Announces Research Collaboration with a Leading US-Based Multinational Animal Health Company
Immuto Scientific, a biotech company advancing structural surfaceomics for first-in-class precision therapeutics, announced today that it has entered into a research collaboration with a leading US-based multinational animal health company. The collaboration is designed to apply Immuto’s state-of-the-art structural proteomics platform to identify novel targets involved in chronic inflammatory dermatologic conditions in companion animals.
Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics
Immuto Scientific announced today the closing of an oversubscribed $8 million Seed 2 financing round and a drug discovery collaboration with Daiichi Sankyo, a global pharmaceutical company. Immuto Scientific is applying its AI-enabled structural surfaceomics platform to a new approach in drug discovery. Backed by the financing, the company will advance its internal oncology pipeline toward IND-enabling studies and extend the platform into additional areas such as immunology and inflammation.
